Swedish Orphan Biovitrum (OM:SOBI) has completed its acquisition of Arthrosi Therapeutics. The deal adds a late stage Phase 3 investigational therapy for gout to Sobi’s portfolio. The transaction stre...

What recent performance says about Swedish Orphan Biovitrum Swedish Orphan Biovitrum (OM:SOBI) has drawn attention after a relatively flat month, with a return close to 0%. This follows a modest gain ...

Swedish Orphan Biovitrum's updated narrative now centers on a slightly higher fair value estimate of SEK 367.09, up from SEK 360.36, paired with a marginally higher discount rate of 5.34% that reflect...

Swedish Orphan Biovitrum (OM:SOBI) has been quietly rewarding patient shareholders, and the recent bounce in the share price is a good moment to step back and reassess what the market is really pricin...

Sobi will make an upfront cash payment of $950m.

Eltel (OM:ELTEL) remains unprofitable, with losses having worsened at a rate of 43.1% per year over the past five years. While revenue is forecast to grow at 2.6% annually, which lags behind the Swedi...

Loomis (OM:LOOMIS) reported robust performance this year, with annual earnings growth accelerating to 17.2% and profit margins improving from 5% to 5.7%. Over the past five years, the company has aver...

Instalco (OM:INSTAL) reported a net profit margin of 2%, down from 3.9% last year, highlighting margin compression even as the company remains profitable. Over the past five years, earnings have decli...

Trying to decide what to do with AAK AB (publ.) stock? You are not alone. Whether you have held through the wild ride or are eyeing a first entry, there is a lot to unpack with this Swedish food ingre...

STOCKHOLM (Reuters) -Swedish police apprehended nine people on Tuesday on suspicion of gross insider stock market trading in 2024 and 2025 ahead of the publication of takeover offers for two companies...